Why Is AstraZeneca Plc Up Today?

AstraZeneca Plc shares rose 0.75% to around 13,964.0p today, a gain of 104.00p, according to the supplied market data.

The gain came as investors moved towards defensive sectors during a global Equity sell-off driven by weakness in US chipmakers and uncertainty ahead of the US midterm elections.

AstraZeneca is the largest company in the FTSE 100, with an index weighting of 8.14% and a Market Capitalisation of about £215 billion.

The shares are also supported by strong nine-month results published at the end of October 2026.

About AstraZeneca Plc

AstraZeneca Plc is a global biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines.

Its main therapy areas are Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies; and Rare Disease through Alexion.

AstraZeneca (LSE:AZN) sells medicines in more than 100 countries and has one of the industry’s broadest late-stage pipelines.

The company has set an ambition to reach $80 billion of Total Revenue by 2030.

Key Reasons Behind Today’s Uptick

Today’s 0.75% gain reflects AstraZeneca’s defensive qualities.

Pharmaceutical Demand is relatively stable regardless of economic conditions, making the sector attractive when markets are volatile.

The company’s recent results also showed continued strong commercial momentum and a reconfirmed full-year outlook.

Shares rallied after the nine-month results as both revenue and profits came in ahead of expectations.

Strong 9M 2026 Financial Performance

AstraZeneca delivered strong growth in the first nine months of 2026.

Total Revenue increased 8% to $46.9 billion, or 7% at constant exchange rates (CER).

Core EPS increased 14% at CER to $8.00.

In the third quarter, Total Revenue rose 7% to $16.2 billion.

Alliance Revenue grew 33% to $2.8 billion, driven by partnered medicines such as Enhertu.

Oncology Is the Main Growth Engine

Oncology is AstraZeneca’s largest and fastest-growing therapy area.

Oncology revenue increased 16% in the first nine months to $21.9 billion, representing 47% of total revenue.

Growth accelerated to 17% in the third quarter.

Key oncology medicines include Tagrisso, Imfinzi, Enhertu and Calquence, which address lung, breast, blood and other cancers.

Rare Disease and Respiratory

Rare Disease revenue grew 11% to $7.5 billion, underpinned by double-digit growth across key medicines.

Respiratory and Immunology grew 10%, supported by newer medicines in asthma and other inflammatory diseases.

These areas help diversify AstraZeneca’s revenue base.

Headwinds in CVRM

Cardiovascular, Renal and Metabolism revenue declined 14% in the first nine months.

The decline reflects loss of exclusivity for Farxiga and Brilinta, as well as volume-based procurement in China.

These headwinds are being offset by growth in other therapy areas, but they remain a drag on overall growth.

Pipeline Progress

AstraZeneca’s pipeline is a key driver of future growth.

The company has reported 12 positive Phase III programme readouts in 2026 to date, with a combined peak revenue potential well in excess of $10 billion.

There have been 47 approvals in major regions since the full-year 2025 results, including first approvals for four new medicines.

First Phase III data have been reported for new molecular entities including tozorakimab in COPD and efzimfotase alfa in hypophosphatasia.

Not every trial succeeds. The CARDIO-TTRansform outcome earlier in the year was a disappointment, but management said its 2030 ambition already assumes both successes and setbacks.

2026 Guidance

AstraZeneca reconfirmed its full-year 2026 guidance at constant exchange rates.

Total Revenue is expected to increase by a mid-to-high single-digit percentage, and Core EPS guidance was also reconfirmed.

Management said the company remains on track to deliver its $80 billion Total Revenue ambition for 2030.

Key Growth Catalysts

The biggest catalyst for AstraZeneca (LSE:AZN) is continued growth in oncology.

New product launches and further Phase III readouts could add significant revenue over the coming years.

Rare Disease and Respiratory and Immunology provide additional growth drivers.

Emerging markets offer long-term expansion opportunities.

Operating leverage from revenue growth can support Core EPS growth.

Pricing and Policy Exposure

Drug pricing is an important Factor for AstraZeneca.

US drug pricing policy, including price negotiation and tariffs, could affect revenue and margins.

Volume-based procurement in China continues to pressure prices for older medicines.

Exchange rate movements also affect reported results because the company reports in US dollars.

Risks

Loss of exclusivity on key medicines remains one of the main risks.

Clinical trial failures could reduce the value of the pipeline.

US drug pricing reforms and trade policy could pressure margins.

Competition in oncology and other therapy areas is intense.

Regulatory and political risks in China could affect growth in that market.

Conclusion

AstraZeneca’s 0.75% rise to 13,964.0p reflects its defensive appeal during a global market sell-off.

Total Revenue rose 7% at CER to $46.9 billion in the first nine months, with Core EPS up 14% to $8.00.

Oncology revenue grew 16% to $21.9 billion and the company has reported 12 positive Phase III readouts in 2026.

Full-year guidance was reconfirmed, and management remains on track for $80 billion of revenue by 2030.

The key factors to monitor are oncology growth, pipeline readouts, new launches, pricing policy and loss-of-exclusivity headwinds.